跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 35,989 条关于
“MagnetisMM-3”
全部
35,989
临床试验
17,738
药物
4,654
机构
1,356
资讯
12,241
2年前
NHS Scotland Approves Elranatamab and Teclistamab for Relapsed/Refractory Multiple Myeloma
9个月前
Elranatamab Plus Iberdomide Combination Achieves 95.5% Response Rate in Relapsed/Refractory Multiple Myeloma
去年
GPRC5D Emerges as Promising Target in Multiple Myeloma Clinical Trials
3年前
Pfizer Launches Phase 3 Trial Testing Elranatamab Triple Combination for Newly Diagnosed Multiple Myeloma
3年前
Elranatamab Achieves 61% Response Rate in Heavily Pretreated Multiple Myeloma Patients
3年前
Novel BCMA-Targeted Therapies and Emerging Agents Transform Treatment Landscape for Relapsed/Refractory Multiple Myeloma
4年前
Bispecific Antibodies Teclistamab and Talquetamab Show Promise in Multiple Myeloma Treatment
2年前
Sanofi's Rilzabrutinib Achieves Primary Endpoint in Phase 3 ITP Trial
去年
Pfizer to Showcase Breakthrough Cancer Therapies at ASCO 2025 with Over 60 Presentations
去年
LAG-3 Inhibitors Show Promise in Cancer Immunotherapy, Market Expected to Surge
第 1 页,共 1225 页
上一页
下一页